Scholar Rock announced the appointment of R. Keith Woods as Chief Operating Officer and Vikas Sinha as Chief Financial Officer. These key executive appointments are part of the company's strategy to scale its operations for the anticipated commercial launch of apitegromab.
Both executives received inducement equity awards, including stock options, restricted stock units (RSUs), and performance-based restricted stock units (PSUs). The stock options for these appointments were granted on May 2, 2025, with an exercise price of $32.91.
These leadership additions, following the appointment of David L. Hallal as CEO, further strengthen Scholar Rock's management team with experienced professionals. Their expertise will be vital in navigating the company's transition to a commercial-stage biopharmaceutical entity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.